Anzeige
Mehr »
Login
Donnerstag, 02.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
"Special Situation"-Aktie mit Multi-Tenbagger-Potenzial im heißesten Rohstoff-Markt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
28 Leser
Artikel bewerten:
(0)

Pharmaceutical Industry Relies on Medical Science Liaisons to Generate Value across a Diverse Set of Customers

CHAPEL HILL, N.C., Aug. 30, 2013 /PRNewswire/ --Medical Science Liaisons (MSLs) are the bridge between a company and key stakeholders that drive marketplace success. The role of MSLs is rapidly growing, with biopharmaceutical and medical device companies increasingly relying on these elite medical specialists to build strong relationships across a diverse set of customers.

To effectively manage MSL groups, which typically sit within Medical Affairs, organizations must continually re-evaluate and adjust their MSL activities and services to ensure they are creating value across all their customer groups. However, concerns about compliance issues and physician access have made this a challenging task for many biopharmaceutical organizations.

To help MSL teams better navigate the ever-changing business and regulatory environment, research and consulting firm Best Practices, LLC has published a report, "Medical Science Liaisons Services Excellence: Generating Value for Diverse Customer Groups." The report, which is based on findings from a primary research study, explores the structure, management and services that are hallmarks of successful MSL groups.

Study objectives included:

  • Explore the methods used by MSLs to serve stakeholders and build stakeholder relationships.
  • Identify roles, responsibilities and service levels provided to Key Opinion Leaders (KOLs).
  • Explore the ways through which MSLs provide services to KOLs. Determine frequency of services during pre- and post-approval stages.

The study provides powerful insights that Medical Affairs leadership can use to drive the success of their MSL groups. Additionally, the report provides information on how the roles of MSLs are evolving in the changing pharmaceutical environment and how regulatory concerns are affecting the MSL landscape.

This study is based on research and information provided by 35 pharmaceutical and medical device executives from 30 companies. The 145-page report provides two segments: the total benchmark class and U.S. only.

To access the full report or to download a complimentary summary containing insights found in this report, click on the following link: http://www3.best-in-class.com/rr1203.htm.

ABOUT BEST PRACTICES, LLC

Best Practices, LLC is a leading benchmarking, consulting and advisory services firm serving biopharmaceutical and medical device companies worldwide. Best Practices, LLC's clients include all the top 10 and 48 of the top 50 global healthcare companies. The firm conducts primary research and consulting using its comprehensive proprietary benchmarking tools and analysis. For more information about Best Practices, LLC visit our Web site at www.best-in-class.com.

SOURCE Best Practices, LLC

Lithium vs. Palladium - Zwei Rohstoff-Chancen traden
In diesem kostenfreien PDF-Report zeigt Experte Carsten Stork interessante Hintergründe zu den beiden Rohstoffen inkl. . Zudem gibt er Ihnen konkrete Produkte zum Nachhandeln an die Hand, inkl. WKNs.
Hier klicken
© 2013 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.